CIK 0001725160 · Non-accelerated filer<br>Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823607803
- Phone
- (858) 263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-20 | Bunker Kevin D. Chief Scientific Officer | Gift | −24,158 | 834,931 | ||
| 2023-11-13 | Blackwell Kimberly Chief Executive Officer | Purchase | +5,000 | $10.29 | $51K | 254,800 |
| 2023-11-10 | Johnson David Michael Director | Purchase | +17,000 | $9.88 | $168K | 144,389 |
| 2023-10-04 | Brownstein Carrie Chief Medical Officer | Sale 10b5-1 | −8,906 | $19.43 | $173K | 107,407 |
| 2023-10-04 | Brownstein Carrie Chief Medical Officer | Sale 10b5-1 | −1,722 | $19.91 | $34K | 105,685 |
| 2023-10-04 | Bunker Kevin D. Chief Scientific Officer | Sale 10b5-1 | −5,085 | $19.43 | $99K | 860,072 |
| 2023-10-04 | Bunker Kevin D. Chief Scientific Officer | Sale 10b5-1 | −983 | $19.91 | $20K | 859,089 |
| 2023-10-04 | Epperly Melissa B, Chief Financial Officer | Sale 10b5-1 | −4,594 | $19.43 | $89K | 388,579 |
| 2023-10-04 | Epperly Melissa B, Chief Financial Officer | Sale 10b5-1 | −888 | $19.91 | $18K | 387,691 |
| 2023-09-11 | Skvarka Jan Director | Sale 10b5-1 | −5,000 | $25.05 | $125K | 47,970 |
| 2023-06-20 | Matrix Capital Management Company, LP 10% owner | Purchase | +4,760,000 | $22.66 | $107.9M | 13,959,973 |
| 2023-06-16 | Johnson David Michael Director | Grant or award | +19,059 | 127,389 | ||
| 2023-06-16 | Kariuki Enoch Director | Grant or award | +16,364 | 38,181 | ||
| 2023-06-16 | Skvarka Jan Director | Grant or award | +16,364 | 52,970 | ||
| 2023-05-31 | Gallagher Cam President | Sale 10b5-1 | −9,242 | $26.40 | $244K | 482,028 |
| 2023-05-31 | Gallagher Cam President | Sale 10b5-1 | −18,526 | $26.21 | $486K | 463,502 |
| 2023-05-26 | Bunker Kevin D. Chief Scientific Officer | Sale 10b5-1 | −80,000 | $30.02 | $2.4M | 15,000 |
| 2023-05-08 | HAUSMAN DIANA Director | Grant or award | +39,732 | 39,732 | ||
| 2023-03-01 | Roth Iris Chief Operating Officer | Grant or award | +52,500 | 52,500 | ||
| 2023-03-01 | Roth Iris Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +297,500 | 297,500 |
Page 5 of 8 · 160 trades